A single‐blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate‐to‐severe mania

  title={A single‐blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate‐to‐severe mania},
  author={Hung-Yu Chan and Shaw-Hua Jou and Yeong‐Yuh Juang and Ching-Jui Chang and Jiahn‐Jyh Chen and Chiung-Hsu Chen and Nan-Ying Chiu},
  journal={Psychiatry and Clinical Neurosciences},
Aims:  Atypical antipsychotics are increasingly used in the management of acute mania. This study was conducted to investigate the efficacy and tolerability of zotepine compared to haloperidol in combination with a mood stabilizer (lithium or valproate) for treatment of acute mania. 

Safety and efficacy of olanzapine monotherapy in treatment‐resistant bipolar mania: a 12‐week open‐label study

To examine the safety and efficacy of olanzapine monotherapy in treatment‐resistant bipolar mania, a large number of patients with a history of mania or attempted mania are enrolled for treatment-resistant mania.

An Open-Label, Randomized, Controlled Trial of Zotepine and Risperidone for Acutely Ill, Hospitalized, Schizophrenic Patients With Symptoms of Agitation

Zotepine seemed to be as effective as risperidone in treating hospitalized, acutely ill, schizophrenic patients with agitation, and had the advantages of lowering hyperuricemia and hyperprolactinemia.

Effects of Lithium on Oxidative Stress

Several studies suggest the importance of lithium in psychopharmacotherapy, particularly in treatment and prophylaxis of bipolar disorder, schizoaffective disorder – bipolar type, cyclothymia and

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder in 2005, with a 2007 update. This second update, in conjunction with the

Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics

Patients With Drug-Naive Bipolar Disorder in Remission After 8 Weeks of Treatment Had Decreased Serum Uric Acid Concentrations

A positive association was found between serum UA and symptom relief in the first episode of manic disorder patients and the results suggest that serum UA concentrations might present potentially a trait marker in bipolar patients.

The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder

The purinergic hypothesis for bipolar disorder emerges in this scenario as a promising target for further research and drug development, given its role in neurotransmission and neuroinflammation that results in behavioral and mood regulation.

Effects of an Atypical Antipsychotic, Zotepine, on Astroglial L-Glutamate Release through Hemichannels: Exploring the Mechanism of Mood-Stabilising Antipsychotic Actions and Antipsychotic-Induced Convulsion

The results suggest that the enhanced astroglial L-glutamatergic transmission induced by ZTP is, at least partially, involved in the mood-stabilising antipsychotic and proconvulsive actions of ZTP.

Taiwan consensus of pharmacological treatment for bipolar disorder



A placebo‐controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia

The aim was to evaluate the efficacy of zotepine in the treatment of acute episodes of schizophrenia.

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.

Risperidone plus a mood stabilizer was more efficacious than a mood stabilizeizer alone, and as efficacious as haloperidol plus a Mood stabilizer, for the rapid control of manic symptoms and was well tolerated.

Zotepine loading in acute and severely manic patients: a pilot study

This open pilot study suggests that zotepine with a median daily dosage of 250 mg/day is effective with a rapid therapeutic effect in severely manic patients.

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.

Aripiprazole had significantly greater efficacy than placebo for the treatment of bipolar disorder patients in acute manic or mixed episodes and was safe and well tolerated in this randomized controlled trial.

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.

Compared with the use of valproate or lithium alone, the addition of olanzapine provided superior efficacy in the treatment of manic and mixed bipolar episodes.

Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol.

In this 6-week trial, zotepine at 150mg/day was as efficacious as haloperidol 9 mg/day in the treatment of Taiwanese patients with schizophrenia and produced fewer extrapyramidal symptoms but had a greater frequency of sedative effects compared to haloperodol.

Acute mania: haloperidol dose and augmentation with lithium or lorazepam.

In this study, 63 acutely psychotic bipolar manic inpatients were randomly assigned to receive double-blind treatment with 1 of 2 haloperidol doses, 25 mg/ day or 5 mg/day, for 21 days and all treatment effects emerged by the fourth day of treatment and persisted.

Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.

In patients with severe manic symptoms, risperidone produced significant improvements in YMRS scores as early as week 1 and substantial changes at end-point and treatment was well tolerated.

Mood stabilisers plus risperidone or placebo in the treatment of acute mania

Risperidone is superior to placebo when used in combination with lithium or divalproex in acute mania, and improved rapidly with significantly greater reductions at week 1 in the ris peridone group compared with the placebo group.

Olanzapine versus placebo in the treatment of acute mania